Update on Investigation and Management of Dyslipidaemias and Cardiovascular Disease Risk - PubMed
4 hours ago
- #lipid management
- #dyslipidemias
- #cardiovascular disease
- Atherosclerotic cardiovascular disease (ASCVD) accounts for a quarter of UK deaths but is often undertreated due to perceived complexity.
- Advances in lipid testing, including lipoprotein(a), apolipoproteins, and genetic testing, enable personalized risk assessment.
- Treatment options have expanded beyond statins to include ezetimibe, PCSK9 monoclonal antibodies, inclisiran, and bempedoic acid.
- Future directions include gene-editing strategies and lipoprotein(a) lowering therapies currently in clinical trials.
- The review aims to simplify recent advances to help clinicians identify high-risk patients and optimize therapy.